FG codeine ban, Emzor Pharma closure a knee jerk response – Experts

| May 9, 2018

article image
The recent ban on codeine-containing cough syrup by the Federal Government, shutting down Emzor Pharmaceuticals Ind. Ltd., Peace Standard Pharmaceutical Limited and Bioraj Pharmaceutical Limited is a knee jerk response to the drug abuse problem experts have said. The ban is echoing in the public space over the drastic measure. Experts want a more logical and comprehensive policy to tackle the incomprehensible and remote causes of this weird and worsening addiction in the country. Cheta Nwanze , Partner at SBM intelligence said the ban is sending a very poor signal about the government and the regulatory agencies. “Codeine is an opiod but not necessarily an essential ingredient but it very effective,” Nwanze said. “Has there been a study for medical evidence, does the country know how many people who depend on medicine with codeine, the knee jerk banning is just an action which if carried out sends a very poor signal to businesses anytime that anything can be at risk.” The Nigerian senate in October 2017 estimated that about 3 million bottles of codeine is consumed daily in Kano and Jigawa States alone. Millions of bottles are consumed all over the country which is rising to epidemic proportions with grave consequences for the youths.

Spotlight

Stiefel, a GSK company

With local operations in 132 countries, Stiefel is a global leader in the field of dermatology. Stiefel is renowned for its 165-year legacy of innovation in the field of skin health, utilizing a combination of expertise, enthusiasm and imagination to deliver the highest quality, most effective prescription and over-the-counter skin care products available.

OTHER ARTICLES

Top Pharmaceutical Firms Urge FDA to Adopt Blockchain for Drug Tracking

Article | February 25, 2020

Leading market participants in the United States pharmaceutical industry, logistics firms, distributors and other stakeholders in the pharma supply chain have come together to publish a report buttressing the need for industry players to adopt blockchain for tracking prescription drugs, following the successful completion of a DLT pilot project with the Food and Drug Administration (FDA), according to reports on February 24, 2020. Though nascent, blockchain technology, the building blocks of Bitcoin (BTC) and other cryptocurrencies are fast gaining ground across various ecosystems, due to its immutability, security, privacy, and other intricate properties. In the latest development, 25 leading manufacturers of pharmaceutical products, logistics partners and other market participants in the pharma supply chain, have published a report that highlights the importance of blockchain technology in drug traceability.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | February 25, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

The Future of Pharma Beyond Blockbusters

Article | February 25, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

5 Pharma Trends and Their Impact on Packaging

Article | February 25, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

Spotlight

Stiefel, a GSK company

With local operations in 132 countries, Stiefel is a global leader in the field of dermatology. Stiefel is renowned for its 165-year legacy of innovation in the field of skin health, utilizing a combination of expertise, enthusiasm and imagination to deliver the highest quality, most effective prescription and over-the-counter skin care products available.

Events